Company Dossier · Health Care
Hims & Hers Health
- MidCap 400
What Hims & Hers Health is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $2.58 billion, up 28% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $0.06 billion, down 50% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.20 billion, up 43% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $0.09 billion.SEC EDGAR filings (10-K)
- Long-term debt issued in the fiscal year to December 31, 2025: $0.97 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (August 10, 2026): sentiment 0.80 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.90 of 1.Palanor Discourse
- Guidance in the last 90 days: 1 outlook figure raised, 2 lowered, 0 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 23, 2026): 8 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $4.2 million on the open market.SEC Form 4
- 506 institutional managers reported a position at June 30, 2026 (+70 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 8 (5 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →Company Posture covers S&P 500 companies.
Credit
How these are built →No bond term sheets or tagged debt on file for Hims & Hers Health yet.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
In the news
Headlines that name Hims & Hers Health, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralHims & Hers Health climbs 10% amid recent volatile trading (HIMS:NYSE)
seekingalpha.com · via Marketaux · Oct 9, 2026
- NeutralHims & Hers Health names new chief accounting officer
seekingalpha.com · via Marketaux · Oct 7, 2026
- NeutralHims & Hers Goes Global - Renewed Growth Prospects With Margin Risks (NYSE:HIMS)
seekingalpha.com · via Marketaux · Oct 1, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 20, 2026LobbyingLobbying report (HIMS & HERS HEALTH, INC.)third_quarter 2026 · $0.3 million
- Oct 15, 2026LobbyingLobbying report (CASSIDY & ASSOCIATES, INC.)third_quarter 2026 · $0.0 million
- Oct 7, 20268-KDirector or officer changeItem 5.02
- Jul 17, 20268-KDirector or officer changeItem 5.02
- Jul 7, 2026Patent
- Jul 1, 20268-KMaterial agreement signedItem 1.01
- Jun 15, 20268-KShareholder vote resultsItem 5.07
- Jun 2, 20268-KMaterial agreement signedItem 1.01
- May 21, 20268-KMaterial agreement signedItem 1.01
- Feb 23, 202610-KAnnual report (10-K)8 risk factors added, 0 removed
- Feb 19, 20268-KMaterial agreement signedItem 1.01
- Nov 4, 2025Patent
- Oct 2, 20258-KDirector or officer changeItem 5.02
- Sep 5, 20258-KMaterial agreement signedItem 1.01
- Jun 17, 20258-KShareholder vote resultsItem 5.07
- May 27, 2025Patent
- May 13, 20258-KMaterial agreement signedItem 1.01
- Apr 21, 20258-KDirector or officer changeItem 5.02
- Feb 24, 202510-KAnnual report (10-K)0 risk factors added, 2 removed
- Nov 21, 20248-KDirector or officer changeItem 5.02
- Oct 22, 2024Patent
- Sep 3, 2024Patent
- Feb 26, 202410-KAnnual report (10-K)0 risk factors added, 1 removed
Peers
Companies in the same sector in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Bio-Rad Laboratories BIO | $2.6B | $0.3B | Jun 30, 2026 |
| Chemed Corporation CHE | $2.6B | $0.3B | Jun 30, 2026 |
| Royalty Pharma RPRX | $2.5B | — | Jun 30, 2026 |
| Natera NTRA | $2.7B | $0.1B | Jun 30, 2026 |
| Exelixis EXEL | $2.4B | $1.2B | Jul 3, 2026 |
| Medpace MEDP | $2.8B | $0.7B | Jun 30, 2026 |
| Envista NVST | $2.9B | $0.3B | Jul 3, 2026 |
| Revvity RVTY | $2.9B | $0.6B | Jul 5, 2026 |